<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01952509</url>
  </required_header>
  <id_info>
    <org_study_id>ML28747</org_study_id>
    <nct_id>NCT01952509</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Multinational, Multicenter, Non Interventional Study, in Patients With Rheumatoid Arthritis (RA) Treated With Tocilizumab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Guatemala: Ministerio de Salud de Guatemala (Guatemala MoH)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, observational study will evaluate the use and efficacy of
      RoActemra/Actemra (tocilizumab) in routine clinical practice in patients with moderate to
      severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment in
      accordance with the local label will be followed for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Proportion of patients on RoActemra/Actemra at 6 months after treatment initiation</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of dose modifications/interruptions</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients on RoActemra/Actemra monotherapy at study entry and at Month 6</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale - Fatigue</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale - severity of pain</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale - morning stiffness</measure>
    <time_frame>aproximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of disease activity</measure>
    <time_frame>approximately 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe rheumatoid arthritis initiating treatment with
        RoActemra/Actemra in accordance with the local label
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria

          -  Patients in whom the treating physician has made the decision to commence
             RoActemra/Actemra treatment (in accordance with the local label); this can include
             patients who have received RoActemra/Actemra treatment within 8 weeks prior to the
             enrolment visit

        Exclusion Criteria:

          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment
             visit

          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for
             compassionate use

          -  Patients who have received treatment with any investigational agent within 4 weeks
             (or 5 half-lives of the investigational agent, whichever is longer) before starting
             treatment with RoActemra/Actemra

          -  Patients with a history of autoimmune disease or any joint inflammatory disease other
             than rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML28747 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Santo Domingo</city>
        <zip>10208</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad de Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Guatemala</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
